MarketScreener Strategies Genmab A/S Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-13 EDT
|
5-day change | 1st Jan Change | ||
| 31.34 USD | -0.25% |
|
+7.11% | +1.75% |
| 08-12 | BNP Paribas Initiates Genmab at Outperform, With $40 Price Target | MT |
| 08-12 | Nordic stocks in North America: AstraZeneca fell 1.0% | FW |
MarketScreener Strategies
Search
 | Genmab: Q2 beat reinforces the investment story; diversification efforts remain on course | August 07, 2026 at 09:12 am |
 | Genmab: Financing weighs now, pipeline pays later | June 23, 2026 at 07:20 am |
| Genmab: Market mispricing creates opportunity as good Q1 reinforces investment thesis | May 09, 2026 at 08:05 am |
| Genmab: 2025 miss and cautious 2026 targets erode investor confidence | February 18, 2026 at 09:09 am |
| Genmab advances on earnings strength and pipeline while lower valuation opens upside | November 07, 2025 at 10:01 am |
| Genmab: A bold shift from defensive to aggressive | September 29, 2025 at 10:45 am |
 | Genmab: From now on, courage to the most patient | April 01, 2025 at 10:57 am |
No results match your criteria
Filters
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- News Genmab A/S
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
